Table 2. Characteristics of linezolid therapy

Characteristics	Overall (n=170, %)	Thrombocytopenia1)		p-value
		No (n=110, %)	Yes (n=60, %)
Route of administration				0.251
IV	77 (45.3)	51 (46.4)	26 (43.3)
PO	50 (29.4)	31 (28.2)	12 (20.0)
Both IV+PO	43 (25.3)	28 (25.5)	22 (36.7)
Indication of linezolid				0.350
Empirical treatment Specific treatment	114 (67.1) 56 (32.9)	77 (70.0) 33 (30.0)	37 (61.7) 23 (38.3)
Microbiology
MRSA	37 (21.8)	22 (20.0)	15 (25.0)	NA
MSSA	6 (3.5)	5 (4.5)	1 (1.7)
MS-CoNS	5 (2.9)	3 (2.7)	2 (3.3)
MR-CoNS	1 (0.6)	1 (0.9)	0
Enterococcus sp.	4 (2.4)	2 (1.8)	2 (3.3)
Streptococcus sp.	5 (2.9)	2 (1.8)	3 (5.0)
Gram-negative	65 (38.2)	39 (35.5)	26 (43.3)
Linezolid dose (dose mg per kg per day)	10.5 (9.1, 12.0)	10.5 (9.2, 12.0)	10.2 (8.6, 12.0)	0.388
Duration of linezolid treatment (days)	12.0 (8.0, 12.0)	10.0 (8.0, 14.0)	14.0 (10.0, 21.0)	<0.001
Previous vancomycin use	42 (24.7)	23 (20.9)	19 (31.7)	0.171

Data are presented as n (%), mean (standard deviation), or median (interquartile range).
IV, intravenous infusion administration; PO, oral administration; MRSA, methicillin-resistant Staphylococcus aureus; MSSA, methicillin-sensitive S. aureus; MS-CoNS, methicillin-sensitive coagulase-negative Staphylococci; MR-CoNS, methicillin-resistant coagulase-negative Staphylococci; NA, not applicable.